NCT00163384已完成3 期
A Comparative Study of Inhaled Ciclesonide 160 mcg/Day vs Budesonide 400 mcg/Day in Patients With Asthma
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 240
- 试验地点
- 20
- 主要终点
- FEV1 absolute values.
研究概览
简要总结
This trial will compare the effectiveness of one dose of ciclesonide against one dose of budesonide in patients with asthma.
The aim of the present trial is to compare the efficacy of ciclesonide versus budesonide on pulmonary function, symptoms and use of rescue medication in patients with asthma. The onset of action and the safety and tolerability of ciclesonide in comparison to budesonide will also be investigated.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •During the last 4 weeks prior to baseline, treatment with an inhaled steroid (dosage: up to 250 mcg fluticasone propionate or equivalent)
- •FEV1 80 - 105% of predicted
- •Healthy with the exception of asthma
- •Written informed consent has been obtained
- •Outpatients
- •Patients who have a history of persistent bronchial asthma for at least 6 months
排除标准
- •Concomitant severe diseases or diseases which are contraindications for the use of inhaled steroids
- •Concomitant COPD (chronic bronchitis or emphysema) and/or other relevant lung diseases causing alternating impairment in lung function
- •An asthma exacerbation or an infection of the lower airways prior to entry into the baseline period
- •Pregnancy
- •Intention to become pregnant during the course of the study
- •Breast feeding
- •Lack of safe contraception
- •Patient is current smoker with 10 or more pack-years
- •Patient is ex-smoker with 10 or more pack-years
结局指标
主要结局
FEV1 absolute values.
次要结局
- FEV1 as percent of predicted
- FVC
- PEF absolute values
- morning and evening PEF from diary
- diurnal PEF fluctuation
- asthma symptom score from diary
- use of rescue medication from diary
- dropout rate due to asthma exacerbations
- number of days with asthma control
- number of symptom free- and rescue medication free days
- onset of effect
- subgroup analysis for ex/current smokers and non-smokers
- AQLQ(S).
- time until first asthma exacerbation
研究者
研究点 (20)
Loading locations...
相似试验
已完成
3 期
Efficacy of Ciclesonide Versus Budesonide in Patients With Asthma (18 to 75 y) (BY9010/M1-137)AsthmaNCT00163397AstraZeneca120
已完成
3 期
Effect of Inhaled Ciclesonide Versus Fluticasone Propionate in Patients With Mild to Moderate Asthma (18 to 65 y) (BY9010/M1-129)AsthmaNCT00163332AstraZeneca30
已完成
3 期
Effects of Inhaled Ciclesonide Versus Fluticasone Propionate Versus Placebo on Lower Leg Growth in Prepubertal Children With Mild Persistent Asthma (6 to 12 y) (BY9010/M1-208)AsthmaNCT00163371AstraZeneca28
已完成
3 期
Efficacy of Ciclesonide and Fluticasone Propionate in Adult Patients With Moderate and Severe Persistent Asthma (18 to 75 y) (BY9010/IT-101)AsthmaNCT00163319AstraZeneca500
已完成
3 期
Efficacy of Ciclesonide Inhaled Once Daily Versus Fluticasone Propionate Inhaled Twice Daily in Children With Asthma (6 to 11 y) (BY9010/M1-206)AsthmaNCT00163462AstraZeneca750